Determining the Repertoire of IGH Gene Rearrangements to Develop Molecular Markers for Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia

被引:7
|
作者
Brisco, Michael J. [1 ,2 ]
Latham, Sue [1 ,2 ]
Sutton, Rosemary [3 ]
Hughes, Elizabeth [1 ,2 ]
Wilczek, Vicki [1 ,2 ]
van Zanten, Katrina [1 ,2 ]
Budgen, Bradley [1 ,2 ]
Bahar, Anita Y. [3 ]
Malec, Maria [3 ]
Sykes, Pamela J. [1 ,2 ]
Kuss, Bryone J. [1 ,2 ]
Waters, Keith
Venn, Nicola C. [3 ]
Giles, Jodie E. [3 ]
Haber, Michelle [3 ]
Norris, Murray D. [3 ]
Marshall, Glenn M. [4 ]
Morley, Alexander A. [1 ,2 ]
机构
[1] Flinders Univ S Australia, Dept Hematol & Genet Pathol, Adelaide, SA, Australia
[2] Med Ctr, Adelaide, SA, Australia
[3] Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia
[4] Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
TIME QUANTITATIVE PCR; CLONAL IMMUNOGLOBULIN; CONCERTED ACTION; HEAVY-CHAIN; CHILDHOOD; RELAPSE; CHILDREN; QUANTIFICATION; INDUCTION; PROTOCOLS;
D O I
10.2353/jmoldx.2009.080047
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia were identified by determining, at the time of diagnosis, the repertoire of rearrangements of the immunoglobulin heavy chain (IGH) gene using segment-specific variable (V), diversity (D), and junctional (J) primers in two different studies that involved a total study population of 75 children and 18 adults. This strategy, termed repertoire analysis, was compared with the conventional strategy of identifying markers using family-specific V, D, and J primers for a variety of antigen receptor genes. Repertoire analysis detected significantly more markers for the major leukemic clone than did the conventional strategy, and one or more IgH rearrangements that were suitable for monitoring the major clone were detected in 96% of children and 94% of adults. Repertoire analysis also detected significantly more IGH markers for minor clones. Some minor clones were quite large and a proportion of them would not be able to be detected by a minimal residual disease test directed to the marker for the major clone. IGH repertoire analysis at diagnosis has potential advantages for the identification of molecular markers for the quantification of minimal residual disease in acute lymphoblastic leukemia cases. An IGH marker enables very sensitive quantification of the major leukemic clone, and the detection of minor clones may enable early identification of additional patients who are prone to relapse. (J mol Diagn 2009, 11:194-200; DOI: 10.2353/jmoldx.2009.080047)
引用
收藏
页码:194 / 200
页数:7
相关论文
共 50 条
  • [21] Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country
    Patkar, Nikhil
    Abu Alex, Ansu
    Bargavi, B.
    Ahmed, Rayaz
    Abraham, Aby
    George, Biju
    Vishwabandya, Auro
    Srivastava, Alok
    Mathews, Vikram
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (04) : 252 - 258
  • [22] B-lineage acute lymphoblastic leukemia of childhood. An institutional experience
    RiveraLuna, R
    CardenasCardos, R
    LealLeal, C
    NavarroAlegria, I
    MezaCoria, C
    GomezMartinez, G
    VegaVega, L
    ARCHIVES OF MEDICAL RESEARCH, 1997, 28 (02): : 233 - 239
  • [23] Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006
    Thorn, Ingrid
    Forestier, Erik
    Thuresson, Britt
    Wasslavik, Carina
    Malec, Maria
    Li, Aihong
    Lindstrom-Eriksson, Elenor
    Botling, Johan
    Barbany, Gisela
    Jacobsson, Stefan
    Olofsson, Tor
    Porwit, Anna
    Sundstrom, Christer
    Rosenquist, Richard
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (02) : 117 - 127
  • [24] Detection of Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia
    Gaipa, Giuseppe
    Basso, Giuseppe
    Biondi, Andrea
    Campana, Dario
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2013, 84 (06) : 359 - 369
  • [25] An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia
    Patkar, Nikhil
    Subramanian, P. G.
    Tembhare, Prashant
    Mandalia, Sneha
    Chaterjee, Gaurav
    Rabade, Nikhil
    Kodgule, Rohan
    Chopra, Karishma
    Bibi, Asma
    Joshi, Swapnali
    Chaudhary, Shruti
    Mascerhenas, Russel
    Kadam-Amare, Pratibha
    Narula, Gaurav
    Arora, Brijesh
    Banavali, Shripad
    Gujral, Sumeet
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2017, 60 (02) : 209 - 213
  • [26] Moleculargenetic Detection of Minimal Residual Disease (MRD) in Children with Acute Lymphoblastic Leukemia
    Koehler, R.
    Bartram, C. R.
    KLINISCHE PADIATRIE, 2013, 225 : S40 - S44
  • [27] The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia
    Xue, Yu-juan
    Wang, Yu
    Jia, Yue-ping
    Zuo, Ying-xi
    Wu, Jun
    Lu, Ai-dong
    Zhang, Le-ping
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (04) : 547 - 555
  • [28] Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
    Della Starza, Irene
    De Novi, Lucia Anna
    Elia, Loredana
    Bellomarino, Vittorio
    Beldinanzi, Marco
    Soscia, Roberta
    Cardinali, Deborah
    Chiaretti, Sabina
    Guarini, Anna
    Foa, Robin
    CANCERS, 2023, 15 (02)
  • [29] Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
    Kruse, Aaron
    Abdel-Azim, Nour
    Kim, Hye Na
    Ruan, Yongsheng
    Phan, Valerie
    Ogana, Heather
    Wang, William
    Lee, Rachel
    Gang, Eun Ji
    Khazal, Sajad
    Kim, Yong-Mi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [30] Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
    Van der Velden, V. H. J.
    Corral, L.
    Valsecchi, M. G.
    Jansen, M. W. J. C.
    De Lorenzo, P.
    Cazzaniga, G.
    Panzer-Gruemayer, E. R.
    Schrappe, M.
    Schrauder, A.
    Meyer, C.
    Marschalek, R.
    Nigro, L. L.
    Metzler, M.
    Basso, G.
    Mann, G.
    Den Boer, M. L.
    Biondi, A.
    Pieters, R.
    Van Dongen, J. J. M.
    LEUKEMIA, 2009, 23 (06) : 1073 - 1079